NYSE:ANVS - Annovis Bio Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $70.00
  • Forecasted Upside: 683.00 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$8.94
▲ +0.33 (3.83%)

This chart shows the closing price for ANVS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Annovis Bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ANVS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ANVS

Analyst Price Target is $70.00
▲ +683.00% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Annovis Bio in the last 3 months. The average price target is $70.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 683.00% upside from the last price of $8.94.

This chart shows the closing price for ANVS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in Annovis Bio.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/30/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/28/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/29/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/27/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/25/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/23/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/24/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/24/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/2/2022LADENBURG THALM/SH SHInitiated CoverageBuyHigh
10/8/2021Maxim GroupInitiated CoverageBuy$70.00Low
7/7/2021Maxim GroupBoost Price TargetBuy$45.00 ➝ $150.00High
5/21/2021Maxim GroupInitiated CoverageBuy$45.00High
5/13/2021Maxim GroupBoost Price TargetBuy$12.00 ➝ $45.00High
(Data available from 5/25/2017 forward)

News Sentiment Rating

0.40 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 5 positive mentions
  • 8 negative mentions
  • 4 very negative mentions
10/27/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/26/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/26/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/25/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/24/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/26/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/25/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/25/2022

Current Sentiment

  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Annovis Bio logo
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
Read More

Today's Range

Now: $8.94
Low: $8.50
High: $8.99

50 Day Range

MA: $11.82
Low: $8.61
High: $14.55

52 Week Range

Now: $8.94
Low: $8.39
High: $132.00

Volume

7,667 shs

Average Volume

58,003 shs

Market Capitalization

$72.99 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.11

Frequently Asked Questions

What sell-side analysts currently cover shares of Annovis Bio?

The following Wall Street analysts have issued research reports on Annovis Bio in the last year: LADENBURG THALM/SH SH, and Maxim Group.
View the latest analyst ratings for ANVS.

What is the current price target for Annovis Bio?

0 Wall Street analysts have set twelve-month price targets for Annovis Bio in the last year. Their average twelve-month price target is $70.00, suggesting a possible upside of 683.0%.
View the latest price targets for ANVS.

What is the current consensus analyst rating for Annovis Bio?

Annovis Bio currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ANVS will outperform the market and that investors should add to their positions of Annovis Bio.
View the latest ratings for ANVS.

How do I contact Annovis Bio's investor relations team?

Annovis Bio's physical mailing address is 1055 Westlakes Drive Suite 300, Berwyn PA, 19312. The company's listed phone number is 610-727-3913 and its investor relations email address is [email protected] The official website for Annovis Bio is www.annovisbio.com. Learn More about contacing Annovis Bio investor relations.